Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
NAUT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.62 - $3.09
Previous CloseN/A
Volume36.21K
Average Volume (3M)204.72K
Market Cap
$82.33M
Enterprise Value-$28.20M
Total Cash (Recent Filing)$147.87M
Total Debt (Recent Filing)$28.18M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Nov 04, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding126,305,120
10 Day Avg. Volume214,904
30 Day Avg. Volume204,725
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.34
Enterprise Value/Revenue-2.94
Enterprise Value/Gross Profit402.92
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$2.50Price Target Upside278.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityCash runway is expected to extend well into '27.
Product DevelopmentManagement highlighted the recent proteoform product success with tau, increasing customer interest, and confidence in ongoing product development for the more important proteome platform.
Technical AdvancementManagement was positive on continued technical advancement of the platform with the late '26 commercial launch timeline reiterated.
Bears Say
Commercial Launch DelayNAUT traded down nearly (20%) after another commercial launch timeline delay, this one a push out to late 2026.
Milestone SetbacksThe company was behind on internal milestones with respect to a major broadscale goal of quantifying a significant number of proteins from a complex sample.
Timeline DelaysNAUT announced its delaying timelines for its planned proteome analysis platform launch to late 2026.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.62 and its highest was $3.09 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $82.33M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Nov 04, 2025 which is in 58 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Jul 31, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.155 by $0.035.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.15.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 126,305,120 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.155. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
Nautilus Biotechnolgy Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (278.79% Upside)
$2.50 (278.79% Upside)
Hedge Fund Trend
Decreased
By 104.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.75%
12-Months-Change
Fundamentals
Return on Equity
-31.55%
Trailing 12-Months
Asset Growth
-21.84%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology (NAUT) is a pioneering company in the biotechnology sector, focused on revolutionizing the field of proteomics. The company's core product is its proprietary platform designed to comprehensively analyze and quantify proteins with unprecedented sensitivity and scale. This breakthrough technology aims to accelerate biomedical research and development, enabling deeper insights into the proteome that can drive advancements in drug discovery, diagnostics, and personalized medicine.
NAUT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, as Nautilus Biotechnology achieved significant scientific milestones, established strategic collaborations, and demonstrated strong financial management. However, there are challenges in terms of market development for proteoforms and limited immediate revenue generation from current collaborations.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$2.50
▲(278.79% Upside)
Technical Analysis
Ownership Overview
35.33% Insiders
3.73% Mutual Funds
40.41% Other Institutional Investors
18.67% Public Companies and
Individual Investors